+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

  • ID: 4851676
  • Report
  • March 2018
  • Region: Global
  • 241 pages
  • Transparency Market Research
1 of 2

Global Cardiovascular Drugs Market: Overview

Cardiovascular drugs are widely used for treating various heart related dysfunction. With increasing number of cardiovascular diseases across the globe is the major driving factor for the growth of the cardiovascular diseases. According to the study conducted by Global Burden of Diseases estimate that the death rate due to CVD is 235 per 100000 in global population. According to WHO, cardiovascular diseases account for 31% deaths globally which is approximately 17.7 million individuals. Out of these 80% of the CVD deaths are due to stroke and heart attacks.  Factors such as sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors responsible for the increase in the number of cardiovascular disorders among young population too.

The global cardiovascular drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, indication, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market.

Global Cardiovascular Drugs Market: Key Segments

Based on drug class the global cardiovascular drugs market is segmented into renin-angiotensin system blockers, beta blockers, diuretics, anti-clotting agents (anti-coagulants and platelet aggregation inhibitors), antihyperlipidemics, other antihypertensive, calcium channel blockers and others. The renin-angiotensin system blockers segment is further classified into ACE inhibitors and angiotensin receptor blockers and the anti-clotting agents segment is further segmented into anti-coagulants and platelet aggregation inhibitors. The drug class segments have been analyzed based on incidence of diseases, awareness regarding early diagnosis and presence of key players in the region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

According to indication the global cardiovascular drugs market is segmented into hypertension, hyperlipidemia, coronary artery diseases, peripheral artery disease, arrhythmia and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Cardiovascular Drugs Market: Regional Outlook

Geographically, the global cardiovascular drugs market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East & Africa (South Africa, GCC Region, Israel and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the cardiovascular drugs market are AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceuticals Company Limited and others.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global CVD Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Overview
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.5. Global CVD Market Analysis and Forecasts, 2015-2025
4.5.3. Market Revenue Projections (US$ Mn)
4.6. CVD Market - Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.9. Market Outlook

5. Global CVD Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings
5.4. Market Value Forecast By Drug Class , 2015-2025
5.4.1. Renin-Angiotensin System Blockers
5.4.1.1. ACE Inhibitors
5.4.1.2. Angiotensin Receptor Blockers
5.4.2. Beta Blockers
5.4.3. Diuretics
5.4.4. Anti-Clotting Agents
5.4.4.1. Anti-Coagulants
5.4.4.2. Platelet Aggregation Inhibitors
5.4.5. Antihyperlipidemics
5.4.6. Other Antihypertensives
5.4.7. Calcium Channel Blockers
5.4.8. Others
5.5. Market Attractiveness By Drug Class

6. Global CVD Market Analysis and Forecasts, By Indications
6.1. Introduction & Definition
6.2. Key Findings
6.4. Market Value Forecast By Indications , 2015-2025
6.4.1. Hypertension
6.4.2. Hyperlipidemia
6.4.3. Coronary Artery Disease
6.4.4. Peripheral Artery Disease
6.4.5. Arrhythmia
6.4.6. Others
6.5. Market Attractiveness By Indications

7. Global CVD Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.4. Market Value Forecast By Distribution Channel , 2015-2025
7.4.1. Hospital Pharmacy
7.4.2. Retail Pharmacy
7.4.3. Online Pharmacy
7.5. Market Attractiveness By Distribution Channel

8. Global CVD Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region

9. North America CVD Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Drug Class , 2015-2025
9.2.1. Renin-Angiotensin System Blockers
9.2.1.1. ACE Inhibitors
9.2.1.2. Angiotensin Receptor Blockers
9.2.2. Beta Blockers
9.2.3. Diuretics
9.2.4. Anti-Clotting Agents
9.2.4.1. Anti-Coagulants
9.2.4.2. Platelet Aggregation Inhibitors
9.2.5. Antihyperlipidemics
9.2.6. Other Antihypertensives
9.2.7. Calcium Channel Blockers
9.2.8. Others
9.3. Market Value Forecast By Indications , 2015-2025
9.3.1. Hypertension
9.3.2. Hyperlipidemia
9.3.3. Coronary Artery Disease
9.3.4. Peripheral Artery Disease
9.3.5. Arrhythmia
9.3.6. Others
9.4. Market Value Forecast By Distribution Channel , 2015-2025
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Market Value Forecast By Country , 2015-2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Indications
9.6.3. By Distribution Channel
9.6.4. By Country

10. Europe CVD Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast By Drug Class , 2015-2025
10.2.1. Renin-Angiotensin System Blockers
10.2.1.1. ACE Inhibitors
10.2.1.2. Angiotensin Receptor Blockers
10.2.2. Beta Blockers
10.2.3. Diuretics
10.2.4. Anti-Clotting Agents
10.2.4.1. Anti-Coagulants
10.2.4.2. Platelet Aggregation Inhibitors
10.2.5. Antihyperlipidemics
10.2.6. Other Antihypertensives
10.2.7. Calcium Channel Blockers
10.2.8. Others
10.3. Market Value Forecast By Indications , 2015-2025
10.3.1. Hypertension
10.3.2. Hyperlipidemia
10.3.3. Coronary Artery Disease
10.3.4. Peripheral Artery Disease
10.3.5. Arrhythmia
10.3.6. Others
10.4. Market Value Forecast By Distribution Channel , 2015-2025
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Market Value Forecast By Country , 2015-2025
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Indications
10.6.3. By Distribution Channel
10.6.4. By Country

11. Asia Pacific CVD Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Class , 2015-2025
11.2.1. Renin-Angiotensin System Blockers
11.2.1.1. ACE Inhibitors
11.2.1.2. Angiotensin Receptor Blockers
11.2.2. Beta Blockers
11.2.3. Diuretics
11.2.4. Anti-Clotting Agents
11.2.4.1. Anti-Coagulants
11.2.4.2. Platelet Aggregation Inhibitors
11.2.5. Antihyperlipidemics
11.2.6. Other Antihypertensives
11.2.7. Calcium Channel Blockers
11.2.8. Others
11.3. Market Value Forecast By Indications , 2015-2025
11.3.1. Hypertension
11.3.2. Hyperlipidemia
11.3.3. Coronary Artery Disease
11.3.4. Peripheral Artery Disease
11.3.5. Arrhythmia
11.3.6. Others
11.4. Market Value Forecast By Distribution Channel , 2015-2025
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Market Value Forecast By Country , 2015-2025
11.5.1. Japan
11.5.2. China
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Indications
11.6.3. By Distribution Channel
11.6.4. By Country

12. Latin America CVD Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Class , 2015-2025
12.2.1. Renin-Angiotensin System Blockers
12.2.1.1. ACE Inhibitors
12.2.1.2. Angiotensin Receptor Blockers
12.2.2. Beta Blockers
12.2.3. Diuretics
12.2.4. Anti-Clotting Agents
12.2.4.1. Anti-Coagulants
12.2.4.2. Platelet Aggregation Inhibitors
12.2.5. Antihyperlipidemics
12.2.6. Other Antihypertensives
12.2.7. Calcium Channel Blockers
12.2.8. Others
12.3. Market Value Forecast By Indications , 2015-2025
12.3.1. Hypertension
12.3.2. Hyperlipidemia
12.3.3. Coronary Artery Disease
12.3.4. Peripheral Artery Disease
12.3.5. Arrhythmia
12.3.6. Others
12.4. Market Value Forecast By Distribution Channel , 2015-2025
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Market Value Forecast By Country , 2015-2025
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Indications
12.6.3. By Distribution Channel
12.6.4. By Country

13. Middle East & Africa CVD Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Class , 2015-2025
13.2.1. Renin-Angiotensin System Blockers
13.2.1.1. ACE Inhibitors
13.2.1.2. Angiotensin Receptor Blockers
13.2.2. Beta Blockers
13.2.3. Diuretics
13.2.4. Anti-Clotting Agents
13.2.4.1. Anti-Coagulants
13.2.4.2. Platelet Aggregation Inhibitors
13.2.5. Antihyperlipidemics
13.2.6. Other Antihypertensives
13.2.7. Calcium Channel Blockers
13.2.8. Others
13.3. Market Value Forecast By Indications , 2015-2025
13.3.1. Hypertension
13.3.2. Hyperlipidemia
13.3.3. Coronary Artery Disease
13.3.4. Peripheral Artery Disease
13.3.5. Arrhythmia
13.3.6. Others
13.4. Market Value Forecast By Distribution Channel , 2015-2025
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Market Value Forecast By Country , 2015-2025
13.5.1. South Africa
13.5.2. GCC Region
13.5.3. Israel
13.5.4. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Indications
13.6.3. By Distribution Channel
13.6.4. By Country

14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Pfizer Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Merck & Co. Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Bristol-Myers Squibb Company
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Bayer AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Boehringer Ingelheim GmbH
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. F. Hoffmann-La Roche Ltd.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Abbott Laboratories
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Gilead Sciences, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Johnson & Johnson
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Astellas Pharma, Inc.
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview
14.3.14. Eli Lilly and Company
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Financial Overview
14.3.14.3. Product Portfolio
14.3.14.4. SWOT Analysis
14.3.14.5. Strategic Overview
14.3.15. Otsuka Holdings Co., Ltd.
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Financial Overview
14.3.15.3. Product Portfolio
14.3.15.4. SWOT Analysis
14.3.15.5. Strategic Overview
14.3.16. Takeda Pharmaceuticals Company Limited
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Financial Overview
14.3.16.3. Product Portfolio
14.3.16.4. SWOT Analysis
14.3.16.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll